Objective: To evaluate the clinical value of serum tumor supplied group of factor (TSGF) in diagnosis of epithelial ovarian cancer. Methods: The serum TSGF was tested in 69 patients with epithelial ovarian cancer, 28...Objective: To evaluate the clinical value of serum tumor supplied group of factor (TSGF) in diagnosis of epithelial ovarian cancer. Methods: The serum TSGF was tested in 69 patients with epithelial ovarian cancer, 28 patients with benign ovarian lesion and 61 healthy women. The serum levels of vascular endothelial growth factor (VEGF) and CA125 were determined in patients with epithelial ovarian cancer and in those with benign ovarian lesion. The correlations of TSGF with VEGF and CA125 were investigated. Results: The serum level of TSGF in patients with epithelial ovarian cancer was obviously higher than in patients with benign ovarian lesion and in healthy women (P<0.01). The serum level of TSGF in patients with epithelial cancer was associated with stage and grade. TSGF was highest in stage III, followed by stage IV, and was lowest in stage I-II. The TSGF level was lower in well-differentiated tumors and was higher in poorly differentiated tumor. There were no significant difference among diagnostic value of TSGF, VEGF, and CA125 in differentiation between epithelial ovarian cancer and benign ovarian lesion (P>0.05). The serum level of TSGF and VEGF and CA125 in patients with epithelial ovarian cancer showed positive correlation (P<0.01, P<0.05, respectively). Conclusion: There is no marked difference in diagnostic value among TSGF, VEGF and CA125. TSGF has a certain value in diagnosis of epithelial ovarian cancer, and is helpful to distinguish epithelial ovarian cancer from benign ovarian lesion.展开更多
This study is to evaluate the clinical value of serum tumor supplied group of factors (TSGF) in diagnosis of canine cancer. 145 dogs with malignant tumors,32 benign diseases,34 dogs with non-tumor diseases,and 6 healt...This study is to evaluate the clinical value of serum tumor supplied group of factors (TSGF) in diagnosis of canine cancer. 145 dogs with malignant tumors,32 benign diseases,34 dogs with non-tumor diseases,and 6 healthy dogs. Biochemical colorimetric assay were used to detect the serum TSGF level. Blood samples were collected at the time of initial diagnostic evaluation,before each chemotherapy session,and at follow-up visits. The serum TSGF level in dogs with malignant tumors,benign diseases,non-tumor diseases and healthy dog were 67. 3 ± 22. 1 U/mL,57. 3 ± 7. 58 U/mL,60. 2 ± 14. 2 U/mL and 54. 6 ± 3. 21 U/mL,the first group was statistically significant higher than the latter (P < 0. 05). 56. 6% malignant patients exceeded the upper limit of the normal reference range (61 U/mL). The samples were classified to groups according clinic stage. The TSGF level from malignant tumor groups were stage I 56. 8 ± 5. 93 U/mL. stage II 66. 7 ± 25. 7 U/mL,stage III 75. 6 ± 22. 7 U/mL and stage IV 73. 9 ± 29. 6 U/mL. Excluding stage I, the TSGF level of all stages are statistically significant higher than healthy group,respectively,the stage III was also statistically significant higher than stage I. Further follow-up study indicated that in entirely insect group,the TSGF level decreased after treatment and kept in low level. In the partly insect group,although the TSGF activity decreased in a short term after surgery,the TSGF level would increase again and kept in high level. From this fact we considered that TSGF level is expected to be a newly potential biomarker in screening neoplastic diseases in veterinary and a monitoring factor for predicting relapse.展开更多
目的探讨肿瘤相关物质(TSGF)与糖抗原19-9(CA19-9)检测在消化道恶性肿瘤(malignant tumors in digestive tract,MTD)诊断中的价值。方法采用比色法检测TSGF,酶免法检测CA19-9。结果TSGF、CA19-9联合检测MTD的敏感性为89.7%,特异性为92....目的探讨肿瘤相关物质(TSGF)与糖抗原19-9(CA19-9)检测在消化道恶性肿瘤(malignant tumors in digestive tract,MTD)诊断中的价值。方法采用比色法检测TSGF,酶免法检测CA19-9。结果TSGF、CA19-9联合检测MTD的敏感性为89.7%,特异性为92.9%,准确性为92.3%,与单项检测CA19-9相比敏感度明显提高。结论联合检测TSGF、CA19-9能提高MTD的诊断率。展开更多
文摘Objective: To evaluate the clinical value of serum tumor supplied group of factor (TSGF) in diagnosis of epithelial ovarian cancer. Methods: The serum TSGF was tested in 69 patients with epithelial ovarian cancer, 28 patients with benign ovarian lesion and 61 healthy women. The serum levels of vascular endothelial growth factor (VEGF) and CA125 were determined in patients with epithelial ovarian cancer and in those with benign ovarian lesion. The correlations of TSGF with VEGF and CA125 were investigated. Results: The serum level of TSGF in patients with epithelial ovarian cancer was obviously higher than in patients with benign ovarian lesion and in healthy women (P<0.01). The serum level of TSGF in patients with epithelial cancer was associated with stage and grade. TSGF was highest in stage III, followed by stage IV, and was lowest in stage I-II. The TSGF level was lower in well-differentiated tumors and was higher in poorly differentiated tumor. There were no significant difference among diagnostic value of TSGF, VEGF, and CA125 in differentiation between epithelial ovarian cancer and benign ovarian lesion (P>0.05). The serum level of TSGF and VEGF and CA125 in patients with epithelial ovarian cancer showed positive correlation (P<0.01, P<0.05, respectively). Conclusion: There is no marked difference in diagnostic value among TSGF, VEGF and CA125. TSGF has a certain value in diagnosis of epithelial ovarian cancer, and is helpful to distinguish epithelial ovarian cancer from benign ovarian lesion.
文摘This study is to evaluate the clinical value of serum tumor supplied group of factors (TSGF) in diagnosis of canine cancer. 145 dogs with malignant tumors,32 benign diseases,34 dogs with non-tumor diseases,and 6 healthy dogs. Biochemical colorimetric assay were used to detect the serum TSGF level. Blood samples were collected at the time of initial diagnostic evaluation,before each chemotherapy session,and at follow-up visits. The serum TSGF level in dogs with malignant tumors,benign diseases,non-tumor diseases and healthy dog were 67. 3 ± 22. 1 U/mL,57. 3 ± 7. 58 U/mL,60. 2 ± 14. 2 U/mL and 54. 6 ± 3. 21 U/mL,the first group was statistically significant higher than the latter (P < 0. 05). 56. 6% malignant patients exceeded the upper limit of the normal reference range (61 U/mL). The samples were classified to groups according clinic stage. The TSGF level from malignant tumor groups were stage I 56. 8 ± 5. 93 U/mL. stage II 66. 7 ± 25. 7 U/mL,stage III 75. 6 ± 22. 7 U/mL and stage IV 73. 9 ± 29. 6 U/mL. Excluding stage I, the TSGF level of all stages are statistically significant higher than healthy group,respectively,the stage III was also statistically significant higher than stage I. Further follow-up study indicated that in entirely insect group,the TSGF level decreased after treatment and kept in low level. In the partly insect group,although the TSGF activity decreased in a short term after surgery,the TSGF level would increase again and kept in high level. From this fact we considered that TSGF level is expected to be a newly potential biomarker in screening neoplastic diseases in veterinary and a monitoring factor for predicting relapse.
文摘目的探讨肿瘤相关物质(TSGF)与糖抗原19-9(CA19-9)检测在消化道恶性肿瘤(malignant tumors in digestive tract,MTD)诊断中的价值。方法采用比色法检测TSGF,酶免法检测CA19-9。结果TSGF、CA19-9联合检测MTD的敏感性为89.7%,特异性为92.9%,准确性为92.3%,与单项检测CA19-9相比敏感度明显提高。结论联合检测TSGF、CA19-9能提高MTD的诊断率。
